BlinkLab Dx 1
Pre-clinical- Indications
- Autism
Company intelligence / Profile preview
BlinkLab’s main product (“BlinkLab Dx 1”) has demonstrated high accuracy in early clinical validation with sensitivity of 91% and specificity of 85% for autism diagnosis. The company has initiated pivotal FDA registrational studies in the US and EU. The technology enables rapid at-home screening using a smartphone app that analyzes children’s responses to video/audio cues via AI algorithms. Regulatory submissions are planned for late 2025 with potential approval in mid-to-late 2026
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BlinkLab.